p.94 抽出テキスト

672. Marfella R, Rossi F, Giugliano D. Hyperglycemia and QT interval: time for re-evaluation. Diabetes Nutr Metab 2001;14:63–65. 673. Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J 2021;42:3727–3738. https://doi.org/10.1093/eurheartj/ ehab560 674. Light PE. Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure. Eur Heart J 2021;42:3739–3740. https://doi.org/10.1093/eurheartj/ehab563 675. Sfairopoulos D, Zhang N, Wang Y, Chen Z, Letsas KP, Tse G, et al. Association between sodium–glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials. Europace 2022;24:20–30. https://doi.org/10.1093/europace/euab177 676. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020;395:709–733. https://doi.org/10.1016/S0140- 6736(20)30045-3 677. Kidney Disease: Improving Global Outcomes, CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013;3:1–150. https://doi.org/10.1038/kisup.2012.73 678. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinineand cystatin C-based equations to estimate GFR without race. N Engl J Med 2021;385: 1737–1749. https://doi.org/10.1056/NEJMoa2102953 679. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012;380:807–814. https://doi.org/10.1016/ S0140-6736(12)60572-8 680. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351: 1296–1305. https://doi.org/10.1056/NEJMoa041031 681. Levey AS, Eckardt K-U, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Kidney Int 2020;97: 1117–1129. https://doi.org/10.1016/j.kint.2020.02.010 682. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073–2081. https://doi.org/10.1016/S0140-6736(10)60674-5 683. Park JI, Baek H, Kim BR, Jung HH. Comparison of urine dipstick and albumin: creatinine ratio for chronic kidney disease screening: a population-based study. PLoS One 2017; 12:e0171106. https://doi.org/10.1371/journal.pone.0171106 684. Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis 2020; 75:84–104. https://doi.org/10.1053/j.ajkd.2019.06.009 685. Levin A, Agarwal R, Herrington WG, Heerspink HL, Mann JF, Shahinfar S, et al. International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney Int 2020;98:849–859. https://doi.org/10.1016/j.kint.2020.07.013 686. Park M, Hsu C-Y, Li Y, Mishra RK, Keane M, Rosas SE, et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol 2012;23: 1725–1734. https://doi.org/10.1681/ASN.2012020145 687. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998;54:1720–1725. https://doi. org/10.1046/j.1523-1755.1998.00154.x 688. Suzuki T, Agarwal SK, Deo R, Sotoodehnia N, Grams ME, Selvin E, et al. Kidney function and sudden cardiac death in the community: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2016;180:46–53. https://doi.org/10.1016/j. ahj.2016.07.004 689. Kono K, Fujii H, Nakai K, Goto S, Shite J, Hirata K-I, et al. Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients with chronic kidney disease. Kidney Int 2012;82:344–351. https://doi.org/10.1038/ki.2012.118 690. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731–1740. https://doi.org/10.1093/ndt/gfg414 691. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2017;7:1–59. https://doi.org/10.1016/j.kisu.2017.04.001 692. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85–97. https://doi.org/10.1161/CIRCULATIONAHA. 106.678342 693. Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, Cass A, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 2013;347:f5680. https://doi. org/10.1136/bmj.f5680 694. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011;305:1119–1127. https://doi.org/10.1001/jama.2011.308 695. Zhu P, Herrington WG, Haynes R, Emberson J, Landray MJ, Sudlow CL, et al. Conventional and genetic evidence on the association between adiposity and CKD. J Am Soc Nephrol 2021;32:127–137. https://doi.org/10.1681/ASN.2020050679 696. Herrington WG, Smith M, Bankhead C, Matsushita K, Stevens S, Holt T, et al. Body-mass index and risk of advanced chronic kidney disease: prospective analyses from a primary care cohort of 1.4 million adults in England. PLoS One 2017;12: e0173515. https://doi.org/10.1371/journal.pone.0173515 697. Cholesterol Treatment Trialists’ (CTT) Collaboration. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diab Endocrinol 2016;4: 829–839. https://doi.org/10.1016/S2213-8587(16)30156-5 698. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebocontrolled trial. Lancet 2011;377:2181–2192. https://doi.org/10.1016/S0140- 6736(11)60739-3 699. Charytan DM, Sabatine MS, Pedersen TR, Im K, Park J-G, Pineda AL, et al. Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am College Cardiol 2019;73:2961–2970. https://doi.org/10.1016/j.jacc.2019.03.513 700. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/ EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019;290:140–205. https://doi.org/10.1016/j. atherosclerosis.2019.08.014 701. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395–1407. https://doi.org/10.1056/NEJMoa0810177 702. Wanner C, Krane V, März W, Olschewski M, Asmus H-G, Krämer W, et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Pressure Res 2004;27:259–266. https://doi.org/10.1159/000080241 703. Reith C, Staplin N, Herrington W, Stevens W, Emberson J, Haynes R, et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrol 2017; 18:147. https://doi.org/10.1186/s12882-017-0545-2 704. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024–2031. https://doi.org/10.1016/S0140- 6736(03)13638-0 705. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456–1462. https://doi.org/10.1056/NEJM199311113292004 706. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving H-H, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869. https://doi.org/10.1056/ NEJMoa011161 707. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860. https://doi.org/10.1056/ NEJMoa011303 708. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870–878. https://doi.org/10.1056/NEJMoa 011489 709. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007;30:1577–1578. https://doi.org/10.2337/dc06-1998 710. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892–1903. https://doi.org/10.1056/NEJMoa1303154 711. Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 2021;9:22–31. https://doi.org/10.1016/ S2213-8587(20)30369-7 712. Cherney DZ, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int 2018; 93:231–244. https://doi.org/10.1016/j.kint.2017.06.017 713. Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, et al. Relative and absolute risk reductions in cardiovascular and kidney outcomes with canagliflozin across KDIGO risk categories: findings from the CANVAS program. Am J Kidney Dis 2021;77:23–34.e1. https://doi.org/10.1053/j.ajkd.2020.06.018 Downloaded from academic.oup.com/eurheartj/article/44/39/4043/7238227 by guest on 07 October 2026